Please login to the form below

Not currently logged in
Email:
Password:

Belgium's TiGenix appoints Dr Gregory Gordon

He takes up a role as head of its US medical development

Gregory GordonBelgium biopharma firm TiGenix has appointed Dr Gregory Gordon to head up its US medical department as part of moves to strengthen its stateside operations.

TiGenix has also appointed Annette Valles-Sukkar as associate director, clinical projects, and both she and Dr Gordon will report to the company’s chief medical officer Dr Marie Paule Richard.

Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel.

Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

Dr Marie Paule Richard said: “We are delighted to welcome Gregory and Annette to TiGenix and to further build the team at our US headquarters in Cambridge, MA.

“Gregory has exceptional experience in drug development generally and specifically with gastrointestinal products. Annette has proven ability to manage large-scale late-stage clinical trials.”

3rd October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics